Clinical Trials Logo

Clinical Trial Summary

.The goal of this interventional study is to estimate the diagnostic performance of plasma biomarkers of interest (Aβ40 and Aβ42, P-Tau and NFL), enabling discrimination between patients with and without a pathophysiological AD process. The main questions it aims to answer are: - to define a threshold value for each of the plasma, - to describe the correlations between the plasma biomarkers of interest and the other biological analyses performed as part of care, in particular triglyceridemia, cholesterolemia, glycemia and proteinemia, - to describe biomarker results in relation to comorbidities, in particular dyslipidemia and diabetes - to describe the final diagnosis and results obtained for plasma biomarkers, for patients with intermediate results according to the A/T/N classification (A-/T+ or A+/T-) Participants will be selected among patients undergoing lumbar puncture for the differential diagnosis of AD at Nancy University Hospital.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06304129
Study type Interventional
Source Central Hospital, Nancy, France
Contact catherine Malaplate, PhD,PharmD
Phone +33383855511
Email c.malaplate@chru-nancy.fr
Status Not yet recruiting
Phase N/A
Start date April 2, 2024
Completion date September 2, 2026